Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoproliferative Disorders 1Lymphoma 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 39Peripheral Blood Stem Cell Transplantation 32fludarabine phosphate 30Busulfan 26Filgrastim 24Cyclosporine 24Mycophenolic Acid 22Antilymphocyte Serum 22Radiotherapy 20Melphalan 16Whole-Body Irradiation 15Tacrolimus 14Methylprednisolone 14Methotrexate 13Cord Blood Stem Cell Transplantation 12Etoposide 10sargramostim 5Thiotepa 5Temozolomide 5Sirolimus 5Rituximab 5Bevacizumab 5aldesleukin 4Therapeutics 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4Carmustine 4pembrolizumab 3Vincristine 3Topotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × beta-Glucans × Sarcoma × Clear all
NCT00087009 2013-03-19

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Memorial Sloan Kettering Cancer Center

Phase 1 Terminated
3 enrolled
LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoproliferative Disorders, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡